SCHEMBL2531133

SCHEMBL2531133

O=C(CCCCCCc1nc(-c2ccccc2)c(-c2ccccc2)o1)NO

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR4A2 P43354 8/20 0.74
RXRA P19793 8/20 0.74
RXRB P28702 8/20 0.74
RXRG P48443 5/20 0.68
NR4A1 P22736 3/20 0.64
NR4A3 Q92570 3/20 0.64
PTGS1 P23219 2/20 0.64
EPHX2 P34913 2/20 0.64
PTGS2 P35354 2/20 0.64
KDM4E B2RXH2 1/20 0.64
ABCC4 O15439 1/20 0.64
C5 P01031 1/20 0.64
LMNA P02545 1/20 0.64
CHRM2 P08172 1/20 0.64
CYP3A4 P08684 1/20 0.64
CHRM1 P11229 1/20 0.64
DRD2 P14416 1/20 0.64
HPGD P15428 1/20 0.64
TSHR P16473 1/20 0.64
TBXA2R P21731 1/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4328651 1.00 NR4A2 (0.74) NR4A2RXRARXRBRXRGNR4A1
SCHEMBL2529192 0.94 NR4A2 (0.67) NR4A2RXRARXRBRXRGNR4A1
SCHEMBL2532060 0.94 RXRA (0.67) NR4A2RXRARXRBRXRGNR4A1
SCHEMBL2529708 0.93 RXRA (0.65) NR4A2RXRARXRBRXRGNR4A1
SCHEMBL2528253 0.93 RXRA (0.68) NR4A2RXRARXRBRXRGNR4A1
SCHEMBL4327039 0.93 RXRA (0.65) NR4A2RXRARXRBRXRGNR4A1
SCHEMBL4334517 0.93 RXRA (0.68) NR4A2RXRARXRBRXRGNR4A1
SCHEMBL2526068 0.90 RXRA (0.61) NR4A2RXRARXRBRXRGNR4A1
SCHEMBL4340132 0.90 RXRA (0.61) NR4A2RXRARXRBRXRGNR4A1
SCHEMBL2526835 0.90 NR4A2 (0.61) NR4A2RXRARXRBRXRGNR4A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1841747-B1 OXAZOLE HYDROXAMIC ACID DERIVATIVES AND USE THEREOF SK BIOPHARMACEUTICALS CO LTD (KR) 2012-09-05 EP claimed
US-20090209596-A1 Oxazole Hydroxamic Acid Derivatives and Use Thereof SK HOLDINGS CO., LTD 2009-08-20 US claimed
US-7521563-B2 Hydroxamic acid derivative and medicine containing the same as active ingredient SHIZUOKA COFFEIN CO., LTD. (JP) 2009-04-21 US claimed
EP-1841747-A1 OXAZOLE HYDROXAMIC ACID DERIVATIVES AND USE THEREOF SK Corporation (KR) 2007-10-10 EP claimed
US-20070208065-A1 Hydroxamic Acid Derivative and Medicine Containing the Same as Active Ingredient SHIZUOKA COFFEIN CO., LTD. (JP) 2007-09-06 US claimed
EP-1787986-A1 HYDROXAMIC ACID DERIVATIVE AND MEDICINE CONTAINING THE SAME AS ACTIVE INGREDIENT SHIZUOKA COFFEIN CO., LTD. (JP) 2007-05-23 EP claimed
WO-2006075888-A1 OXAZOLE HYDROXAMIC ACID DERIVATIVES AND USE THEREOF SK CORPORATION (KR) 2006-07-20 WO claimed
EP-1841747-B1 OXAZOLE HYDROXAMIC ACID DERIVATIVES AND USE THEREOF SK BIOPHARMACEUTICALS CO LTD (KR) 2012-09-05 EP disclosed
EP-1841747-B1 OXAZOLE HYDROXAMIC ACID DERIVATIVES AND USE THEREOF SK BIOPHARMACEUTICALS CO LTD (KR) 2012-09-05 EP disclosed
US-8039634-B2 Oxazole hydroxamic acid derivatives and use thereof SK HOLDINGS CO., LTD. (KR) 2011-10-18 US disclosed
US-8039634-B2 Oxazole hydroxamic acid derivatives and use thereof SK HOLDINGS CO., LTD. (KR) 2011-10-18 US disclosed
US-8039634-B2 Oxazole hydroxamic acid derivatives and use thereof SK HOLDINGS CO., LTD. (KR) 2011-10-18 US disclosed
US-20090209596-A1 Oxazole Hydroxamic Acid Derivatives and Use Thereof SK HOLDINGS CO., LTD 2009-08-20 US disclosed
US-20090209596-A1 Oxazole Hydroxamic Acid Derivatives and Use Thereof SK HOLDINGS CO., LTD 2009-08-20 US disclosed
US-7521563-B2 Hydroxamic acid derivative and medicine containing the same as active ingredient SHIZUOKA COFFEIN CO., LTD. (JP) 2009-04-21 US disclosed
EP-1841747-A1 OXAZOLE HYDROXAMIC ACID DERIVATIVES AND USE THEREOF SK Corporation (KR) 2007-10-10 EP disclosed
US-20070208065-A1 Hydroxamic Acid Derivative and Medicine Containing the Same as Active Ingredient SHIZUOKA COFFEIN CO., LTD. (JP) 2007-09-06 US disclosed
EP-1787986-A1 HYDROXAMIC ACID DERIVATIVE AND MEDICINE CONTAINING THE SAME AS ACTIVE INGREDIENT SHIZUOKA COFFEIN CO., LTD. (JP) 2007-05-23 EP disclosed
WO-2006075888-A1 OXAZOLE HYDROXAMIC ACID DERIVATIVES AND USE THEREOF SK CORPORATION (KR) 2006-07-20 WO disclosed
WO-2006075888-A1 OXAZOLE HYDROXAMIC ACID DERIVATIVES AND USE THEREOF SK CORPORATION (KR) 2006-07-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090209596-A1 Oxazole Hydroxamic Acid Derivatives and Use Thereof HDAC1, HDAC5, HDAC7 NR4A2 1465/4885RXRA 1264/4885RXRB 1916/4885
US-20070208065-A1 Hydroxamic Acid Derivative and Medicine Containing the Same as Active Ingredient IL6, IL1A, TNF NR4A2 2123/4885RXRA 883/4885RXRB 969/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.